Cardiovascular Drugs and Therapy最新文献

{"title":"Comment on \"Vagus Nerve Stimulation by Focused Ultrasound Attenuates Acute Myocardial Ischemia/Reperfusion Injury Predominantly Through Cholinergic Anti-inflammatory Pathway\".","authors":"Ahmad Shabbir, Muhammad Asim Agha","doi":"10.1007/s10557-025-07767-1","DOIUrl":"https://doi.org/10.1007/s10557-025-07767-1","url":null,"abstract":"","PeriodicalId":9557,"journal":{"name":"Cardiovascular Drugs and Therapy","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2025-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144943983","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Teenagers Cardiovascular Risk: The Underrated Role of Lipoprotein(a).","authors":"Muhammad Abdullah Jawaid, Anosha Ramzan","doi":"10.1007/s10557-025-07765-3","DOIUrl":"https://doi.org/10.1007/s10557-025-07765-3","url":null,"abstract":"","PeriodicalId":9557,"journal":{"name":"Cardiovascular Drugs and Therapy","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2025-08-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144871636","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Optimizing P2Y12 Inhibitor Therapy in Post-PCI Patients Through Genotype-Guided Strategies: A Systematic Review and Meta-Analysis.","authors":"Mohammad Hamza, Mubashar Karamat, Khaled M Harmouch, Sardar M Alamzaib, Sidra Jabeen, Jawad Basit, Karan Bhanushali, Rohan Ved, Amna Rashdi, Muhammad Usman Almani, Moinuddin Syed, Yasar Sattar, M Chadi Alraies","doi":"10.1007/s10557-025-07747-5","DOIUrl":"https://doi.org/10.1007/s10557-025-07747-5","url":null,"abstract":"<p><strong>Background: </strong>Clopidogrel non-responder is a common dilemma in the management of post-percutaneous coronary intervention (PCI) management. Clopidogrel is metabolized by CYP2C19. The genetic variations in CYP2C19 can affect the efficacy and bioavailability of the drug that can be checked via genotype testing of the gene. This study evaluates the impact of genotype versus conventional guided P2Y12 inhibitor therapy on post-PCI patient outcomes.</p><p><strong>Methods: </strong>Guided by PRISMA and AMSTAR-2, we analyzed 10 trials comparing genotype-guided and conventional P2Y12 inhibitor therapy in post-PCI patients. Our search, spanning up to October 2022 across major databases, focused on adult populations undergoing PCI, assessing outcomes like mortality, MACE, myocardial infarction, stroke, stent thrombosis, and bleeding events.</p><p><strong>Results: </strong>A total of 10 studies involving 4300 patients were selected in pooled analysis, genotype-guided therapy markedly reduced all-cause mortality (RR: 0.59; 95% CI: 0.37-0.95) and MACE (RR: 0.66; 95% CI: 0.49-0.88), without a significant increase in bleeding events (RR: 0.83; 95% CI: 0.61-1.14). Furthermore, significant reductions were observed in myocardial infarction (RR: 0.59; 95% CI: 0.44-0.78) and stent thrombosis (RR: 0.55; 95% CI: 0.3-0.996), with stroke also seeing a decrease (RR: 0.56; 95% CI: 0.35-0.9).</p><p><strong>Conclusion: </strong>Genotype-guided P2Y12 inhibitor therapy significantly improves outcomes for post-PCI patients, reducing mortality, MACE, myocardial infarction, and stent thrombosis without increasing bleeding risk. These findings support the integration of genetic testing into clinical decision-making for DAPT optimization.</p>","PeriodicalId":9557,"journal":{"name":"Cardiovascular Drugs and Therapy","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2025-08-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144815810","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Relationship and Mechanism of CD27 with Coronary Atherosclerotic Heart Disease.","authors":"Xue Fei Song, Fei Lin, Zhi Gang Chen, Guo An Zhao, Si Yu Sun, Jun Pu","doi":"10.1007/s10557-025-07740-y","DOIUrl":"https://doi.org/10.1007/s10557-025-07740-y","url":null,"abstract":"<p><p>CD27, as a member of the immune checkpoints (IC), is physiologically expressed on various immune cells, with CD70 being its only known ligand. Together, they play a significant role in the co-stimulation and activation of T and B cells, regulating the body's immune response. Currently, the CD27/CD70 pathway shows great potential in the clinical treatment of tumors. Previous studies have found that immune checkpoint inhibitors (ICIs) provide significant benefits to cancer patients while also causing various adverse reactions, including cardiovascular diseases. The critical role of inflammation and adaptive immunity in coronary atherosclerotic heart disease (CAD) is widely recognized. Studies have found that the absence of CD27 or the blockade of the CD27/CD70 pathway exacerbates the occurrence of CAD. This review mainly summarizes the impact and mechanisms of CD27 and the CD27/CD70 pathway on CAD through immune regulatory pathways, providing important theoretical support for clinical treatment and prevention of adverse events in coronary heart disease, as well as new therapeutic strategies.</p>","PeriodicalId":9557,"journal":{"name":"Cardiovascular Drugs and Therapy","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2025-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144798239","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effectiveness and Safety of Direct Oral Anticoagulants Versus Warfarin in Patients with Atrial Fibrillation and Cancer: A Target Trial Emulation from SEER-Medicare Database.","authors":"Bang Truong, Lori Hornsby, Brent Fox, Chiahung Chou, Jingyi Zheng, Jingjing Qian","doi":"10.1007/s10557-024-07589-7","DOIUrl":"10.1007/s10557-024-07589-7","url":null,"abstract":"<p><strong>Background: </strong>Direct oral anticoagulants (DOACs) are preferred over warfarin in patients with atrial fibrillation (AFib). However, their safety and effectiveness in patients with AFib and cancer are inconclusive.</p><p><strong>Methods: </strong>We conducted a retrospective cohort study by emulating a target trial. Patients with a record of cancer (breast, prostate, or lung), newly diagnosed with AFib initiated DOACs or warfarin within 3 months after AFib diagnosis from the 2012-2019 Surveillance, Epidemiology, and End Results (SEER)-Medicare database were included. We compared the risk of ischemic stroke, major bleeding, and secondary outcomes (venous thromboembolism, intracranial bleeding, gastrointestinal bleeding, and non-critical site bleeding) between patients who initiated DOACs and warfarin. Inverse probability treatment weights and inverse probability censoring weights were used to adjust imbalanced patient and disease characteristics and loss to follow-up between the two groups. Weighted pooled logistic regression were used to estimate treatment effect with hazard ratios (HRs) with 95% confidence interval (95% CIs).</p><p><strong>Results: </strong>The incidence rates of stroke and major bleeding between DOAC and warfarin initiators were 9.97 vs. 9.91 and 7.74 vs. 9.24 cases per 1000 person-years, respectively. In adjusted intention-to-treat analysis, patients initiated DOACs had no statistically significant difference in risk of ischemic stroke (HR = 0.87, 95% CI 0.52-1.44) and major bleeding (HR = 1.14, 95% CI 0.77-1.68) compared to those initiated warfarin. In adjusted per-protocol analysis, there was no statistical difference in risk of ischemic stroke (HR = 1.81, 95% CI 0.75-4.36) and lower risk for major bleeding, but the 95% CI was wide (HR = 0.35, 95% CI 0.12-0.99) among DOAC initiators compared to warfarin initiators. The benefits in secondary outcomes were in favor of DOACs. The findings remained consistent across subgroups and sensitivity analyses.</p><p><strong>Conclusion: </strong>DOACs are safe and effective alternatives to warfarin in the management of patients with AFib and cancer.</p>","PeriodicalId":9557,"journal":{"name":"Cardiovascular Drugs and Therapy","volume":" ","pages":"823-835"},"PeriodicalIF":3.1,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12296962/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141283001","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Transporter Genes and statin-induced Hepatotoxicity.","authors":"Seo-A Choi, Jung Sun Kim, Yoon-A Park, Da Hoon Lee, Minju Park, Jeong Yee, Yoonkyung Chang, Tae-Jin Song, Hye Sun Gwak","doi":"10.1007/s10557-024-07580-2","DOIUrl":"10.1007/s10557-024-07580-2","url":null,"abstract":"<p><strong>Purpose: </strong>Hepatotoxicity has emerged as a major cause of statin treatment interruption. Although organic anion-transporting polypeptide 1B1 (SLCO1B1), multidrug resistance protein 1 (ABCB1), and breast cancer resistance protein (ABCG2) have been identified as transporters of statins, knowledge of their role in statin-associated hepatotoxicity remains limited. Therefore, we aimed to conduct a comprehensive analysis to elucidate the association between hepatotoxicity and SLCO1B1, ABCB1, and ABCG2 polymorphisms.</p><p><strong>Methods: </strong>This study retrospectively analyzed prospectively collected samples. We selected 10 single nucleotide polymorphisms (SNPs) of SLCO1B1, 9 SNPs of ABCB1, and 12 SNPs of ABCG2. We developed two models for multivariable analyses (Model I: clinical factors only; Model II: both clinical and genetic factors), and the attributable risk (%) of variables in Model II was determined.</p><p><strong>Results: </strong>Among 851 patients, 66 (7.8%) developed hepatotoxicity. In Model I, lipophilic statins, atrial fibrillation (Afib), and diabetes mellitus showed a significant association with hepatotoxicity. In Model II, lipophilic statins and Afib, SLCO1B1 rs11045818 A allele, SLCO1B1 rs4149035 T allele, and ABCG2 rs2622629 TT genotype were associated with higher hepatotoxicity risk. Among them, the SLCO1B1 rs11045818 A allele exhibited the highest attributable risk (93.2%). The area under the receiver operating characteristic curve in Model I was 0.62 (95% CI: 0.55-0.69), and it was increased to 0.71 in Model II (95% CI: 0.64-0.77).</p><p><strong>Conclusion: </strong>This study investigated the correlation between hepatotoxicity and polymorphisms of transporter genes in patients taking statins. The findings could help improve personalized treatments for patients receiving statin therapy.</p>","PeriodicalId":9557,"journal":{"name":"Cardiovascular Drugs and Therapy","volume":" ","pages":"801-810"},"PeriodicalIF":3.1,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141160996","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Amplification of Cardioprotective Response of Remote Ischemic Preconditioning in Rats by Quercetin: Potential Role of Activation of mTOR-dependent Autophagy and Nrf2.","authors":"Ayush Kandpal, Kuldeep Kumar, Satnam Singh, Harlokesh Narayan Yadav, Amteshwar Singh Jaggi, Dhandeep Singh, Dimple Sethi Chopra, Leonid Maslov, Nirmal Singh","doi":"10.1007/s10557-024-07595-9","DOIUrl":"10.1007/s10557-024-07595-9","url":null,"abstract":"<p><strong>Objectives: </strong>Noninvasive remote ischemic preconditioning (RIPC) is a practical, acceptable, and feasible conditioning technique reported to provide cardioprotection in myocardial ischemia-reperfusion injury (MIRI). It has been well-reported that quercetin possesses antioxidant and anti-inflammatory properties. This study investigates the modification of the cardioprotective response of RIPC by quercetin.</p><p><strong>Methods: </strong>Adult Wistar rats were randomized into 12 groups of six animals each. MIRI was induced by subjecting the isolated hearts of Wistar rats to global ischemia for 30 min, succeeded by reperfusion of 120 min after mounting on the Langendorff PowerLab apparatus. Hind limb RIPC was applied in four alternate cycles of ischemia and reperfusion of 5 min each by tying the pressure cuff before isolation of hearts.</p><p><strong>Results: </strong>MIRI was reflected by significantly increased infarct size, LDH-1, and CK-MB, TNF-α, TBARS, and decreased GSH, catalase, and hemodynamic index, and modulated Nrf2. Pretreatment of quercetin (25 and 50 mg/kg; i.p.) significantly attenuated the MIRI-induced cardiac damage and potentiated the cardioprotective response of RIPC at the low dose. Pretreatment of ketamine (10 mg/kg; i.p.), an mTOR-dependent autophagy inhibitor, significantly abolished the cardioprotective effects of quercetin and RIPC.</p><p><strong>Conclusions: </strong>The findings highlight the modification of the cardioprotective effect of RIPC by quercetin and that quercetin protects the heart against MIRI through multiple mechanisms, including mTOR-dependent activation of autophagy and Nrf-2 activation.</p>","PeriodicalId":9557,"journal":{"name":"Cardiovascular Drugs and Therapy","volume":" ","pages":"721-736"},"PeriodicalIF":3.1,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141445699","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Moderate-Intensity Atorvastatin and Ezetimibe Combination Therapy Versus High-Intensity Atorvastatin in Patients with Angina Pectoris who Underwent Percutaneous Coronary Intervention.","authors":"Seo Young Sohn, Yun Jin Kim, Joon-Hyung Doh, Sung Woo Cho","doi":"10.1007/s10557-025-07729-7","DOIUrl":"https://doi.org/10.1007/s10557-025-07729-7","url":null,"abstract":"<p><strong>Background: </strong>Whether moderate-intensity statin and ezetimibe combination therapy is beneficial compared to high-intensity statin monotherapy in patients with angina pectoris who underwent percutaneous coronary intervention (PCI) remains unclear. We aimed to investigate the effect of moderate-intensity atorvastatin with ezetimibe combination therapy after PCI in patients with angina pectoris, but not myocardial infarction (MI), in real-world practice.</p><p><strong>Methods: </strong>This retrospective cohort study used data from the Korean National Health Insurance Database. Altogether 6784 patients who underwent PCI between 2015 and 2018 received either moderate-intensity atorvastatin (10 and 20 mg) and ezetimibe 10 mg (n = 4682) or high-intensity atorvastatin (40 and 80 mg; n = 2102). The primary outcome was a composite of cardiovascular death, MI, coronary revascularization, and stroke. Subgroup analyses were performed on the basis of baseline comorbidities.</p><p><strong>Results: </strong>During the follow-up (mean duration of 4 years), incidence rates of the primary outcome were 70.14 and 62.05 per 1000 person-years in the moderate-intensity atorvastatin plus ezetimibe and high-intensity atorvastatin groups, respectively, with no significant differences in the risk of primary outcome between the two groups [hazard ratio (HR), 0.99; 95% confidence interval (CI) 0.90-1.10]. However, in patients with underlying chronic kidney disease (CKD), moderate-intensity atorvastatin with ezetimibe combination therapy was associated with a lower risk of primary outcome compared to high-intensity atorvastatin therapy (HR 0.40, 95% CI 0.18-0.86).</p><p><strong>Conclusion: </strong>In this real-world cohort study, there was no significant difference in cardiovascular outcomes between moderate-intensity atorvastatin plus ezetimibe combination therapy and high-intensity atorvastatin monotherapy in patients with angina pectoris who underwent PCI. Moderate-intensity atorvastatin and ezetimibe combination therapy may be beneficial, particularly in patients with CKD.</p>","PeriodicalId":9557,"journal":{"name":"Cardiovascular Drugs and Therapy","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144759195","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Which Therapies Should Be Initiated After Optimizing Statins? A Multi-pillar Strategy for ASCVD Risk Reduction.","authors":"Olamide Oyenubi, Xiaoming Jia","doi":"10.1007/s10557-025-07671-8","DOIUrl":"10.1007/s10557-025-07671-8","url":null,"abstract":"","PeriodicalId":9557,"journal":{"name":"Cardiovascular Drugs and Therapy","volume":" ","pages":"709-710"},"PeriodicalIF":3.1,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143001069","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction to: Non-Invasive Local Acoustic Therapy Ameliorates Diabetic Heart Fibrosis by Suppressing ACE-Mediated Oxidative Stress and Inflammation in Cardiac Fibroblasts.","authors":"Liqing Weng, Lu Li, Kun Zhao, Tianhua Xu, Yukang Mao, Huanyu Shu, Xuguan Chen, Ji Chen, Jian Wu, Xiasheng Guo, Juan Tu, Dong Zhang, Wei Sun, Xiangqing Kong","doi":"10.1007/s10557-025-07734-w","DOIUrl":"10.1007/s10557-025-07734-w","url":null,"abstract":"","PeriodicalId":9557,"journal":{"name":"Cardiovascular Drugs and Therapy","volume":" ","pages":"703"},"PeriodicalIF":3.1,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144483221","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}